INTRODUCTION
During the last two decades we have witnessed an explosive growth in the domain of human reproductive knowledge. The application of this information to solving human infertility has allowed numerous couples to fulfill their procreative reproductive wishes. These new forms of human conception (related primarily to IVF and embryo transfer) have advanced ahead of sociolegal discussions and regulations. Today the practice of IVF (and some similar but modified methods) is an accepted treatment for the alleviation of human disease, i.e., infertility, and not an experimental technique (1) . The risk:benefit ratio of IVF (potential complications of ovarian hyperstimulation and multiple pregnancies versus attainment of healthy pregnancies) is clearly favorable for society as a whole (1) . Nevertheless, we must continue to apply strict monitoring criteria for the application of the highest-quality laboratory practices, reports of clinical successes/failures, and biomedical reproductive research.
Ellis has recently stated that "the overwhelming majority of American institutions conducting and supporting biomedical research have for years formally pledged that all their research--irrespective of funding source--will comply with the regulations for protection of human subjects of the U.S. Depart-
The opinions presented in this column are those of its authors and do not necessarily reflect those of the journal and its editors, publisher, and advertisers. (2) (3) (4) . It is the duty of each Institutional Review Board (IRB) to review, approve, and monitor all clinical research involving human subjects following those regulations. The required basic components of informed consent and the criteria for IRB approval of research should be complied with by all university-and hospital-established institutions (private centers performing basic or clinical research should also be affiliated to a university or hospital group for the purpose of seeking IRB approval). An adequate composition of the IRB is required to assure a wide spectrum of independent opinions and backgrounds (3) .
Additional protections pertain to research activities involving human fetuses, pregnant women and IVF (3) . Couples undergoing IVF may represent a vulnerable category of subjects due to the psychological implications of long-term infertility and because gametes and embryos may be amenable to research and clinical manipulations. General limitations for IVF-related research activities include (a) completion of appropriate studies on animals and nonpregnant women, (b) informed consent of proSpective mother and father (whenever potential for fertilization and embryo formation exists), and (c) minimized risks to the implanting and developing embryo (3) .
Research studies involving the collection of existing data, documents, records, pathological specimens, or diagnostic specimens are exempt from these regulations (i.e., they do not require full IRB approval and patient consent forms) if the sources of research are publicly available or if the information is recorded by the investigator in such a manner that subjects cannot be identified, directly or through identifiers linked to the subjects (3). The process of assigning exempt status is not an absolute one; rather it lies in a gray zone and is open to varied interpretations. Our opinions related to the use of human gametes and clinical investigations within assisted reproduction follow.
The category of exemption could potentially apply to studies involving spermatozoa (collected for diagnostic purposes), usually considered as "discarded material," unless those sperm cells are going to be used in experiments where potential for fertilization of a human oocyte may exist. Therefore, spermatozoa used for investigations including morphological, biochemical, or functional tests and bioassays using either heterologous oocytes (i.e., hamster oocytes) or homologous--but nonviable--human oocytes (i.e., oocytes rendered nonviable after salt storage or freezing without cryoprotectants), could potentially be considered exempt. Oocytes obtained from pathological specimens (ovaries) or from IVF treatment (immature, arrested, or unfertilized, typically considered "discarded material") and used for morphological, biochemical, functional, or chromosomal studies might also be considered exempt according to the interpretation of the above mentioned definition provided that they do not entail future potential for fertilization (i.e., insemination with Viable sperm).
However, IRBs have the authority to request notification about these activities. This is the case at Eastern Virginia Medical School, where investigators are required to submit research protocols involving human subjects to the IRB even if studies are considered initially exempt (these protocols are reviewed internally, although no consent form may be required). Additionally, even if the IRB grants exemption, our IRB recommends that investigators provide written information outlining the proposed activities to the research subjects (this is performed in the form of a short written statement that informs the subject about the research and gives him/her the opportunity to refuse participation) (3). This policy is being followed for all prospectively designed studies using human gametes (as mentioned above) at The Jones institute.
It is clear that the purpose of the IRB actions is to protect the principle that the rights of individuals should be respected; whenever possible, even in exempt cases, it may be advisable to seek subjects' consent for participation in research. Even when the research material may be considered "existing" or "discarded" (as spermatozoa or oocytes), there may be circumstances in which the IRB should require the investigator conducting a prospectively designed study to secure patients' consent (no exemption is granted). The concepts of "discarded material" and "potential for fertilization" may be imprecise or too vague for interpretation by investigators, tn our opinion, the use of "discarded" sperm in studies where contact with a viable human oocyte is possible and the use of "discarded" oocytes for the purpose of insemination with viable human sperm are definitively not exempt and require full IRB approval and patients' consent. This should be the case even if the study protocol calls for arrest of embryo development at very early stages (i.e., at the pronuclear stage or at syngamy). Immature and mature oocytes obtained at the time of aspiration for IVF and not inseminated upon the couple's wishes (in the case of couples electing to inseminate a restricted number of oocytes and declining oocyte cryopreservation) should also pertain to this category since these oocytes are not "pathologic" tissue. It is our view that investigations related to the use of those oocytes for the purpose of stimulating maturation and/or for cryopreservation purposes should be included in this category. The IRB is the final adviser in this regard and may have to cross the fine line between requesting full approval and establishing the category of exemption. Therefore, it is imperative that all investigators performing any research involving human gametes submit their protocols to their respective IRBs to inquire about exemption or full review status.
Controversy exists as to the moral and legal status of the embryo (5). The Ethics Committee of the American Fertility Society has stated that "the status ofthe preembryo should be different from that of either the earlier gametes or the still later embryonic stages." Furthermore, it has recommended that "the status of the preembryo should also be different from that assigned to isolated cells, tissues and organs..." and that "the existing preembryo must be treated with respect because it is human, but it must also be treated with concern beyond respect as long as the possibility exists that it may achieve full human developmental status in the future" (6) . In addition, the National Institutes of Health Human Embryo Research Panel and ethical advisory bod-ies in other countries have set forth conditions under which donated embryos may ethically be used in approved research (7).
Therefore, in our opinion, all studies involving potential for fertilization (using "discarded material"--gametes--donated for experimentation by the infertile couples or utilizing gamete donors), embryos (resulting from normal or abnormal fertilization), and clinical investigations within the IVF setting (i.e., use of new hormonal preparations, drugs, or techniques) should require full IRB approval and patients' consent. Unlike the standard practices of IVF and embryo cryopreservation, the methods of intracytoplasmic sperm injection (ICSI) (and other techniques of assisted fertilization by oocyte micromanipulation or other means), assisted hatching, and embryo biopsy performed for genetic diagnosis should not as yet be considered accepted standard therapies because of the possibility of risks which are currently unforeseeable (there may be risks not yet identified). Consequently, these practices should, for the time being, be considered experimental and require IRB approval and parents' consent with a clear understanding of benefits and risks. Recent data related to the normalcy of children born with ICSI have been reassuring. Our institution, as well as others, may soon reevaluate this policy, and ICSI may thereforebe considered standard therapy for treating male infertility in the very near-future.
The creation of human embryos for the sole purpose of research using gametes from patients or donors demands special IRB discussion and surveillance. As Edwards and Brody have claimed, "The most vexing ethical issues involve techniques with less obvious benefit to society and greater potential for abuse. At present, these issues include, but are not limited to, genetic modulation of the embryo, selective pregnancy termination following the transfer of many embryos, and research on viable embryos wanted by their parents" (1) .
Individual centers and IRBs should analyze these issues carefully both ethically and clinically and develop new standards to prevent improper uses and their consequences. Discussions at different levels (i.e., Society for Assisted Reproduction, American Society for Reproductive Medicine, ethics committees, and the public in general) should be encouraged.
In summary, all research protocols within the assisted reproductive setting should be reviewed by the IRB. Only a very limited number of cases (use of "discarded" material) may be considered exempt, but the IRB should make the final decision. In exempt studies, a written information letter is recommended. All other research studies using human gametes and embryos require full IRB review and patients' consent. As of today, only the practice of IVF and embryo cryopreservation, in our opinion, should be considered standard and established therapies.
The views expressed here are the result of our experience in basic and clinical research in assisted reproduction, exchanges with infertile patients, discussions within our internal Ethics Committee, and our interpretation of current federal rules and regulations. It is our belief that serious scientific and technological advances should always rest on a solid philosophical and ethical foundation and be geared toward serving society as a whole.
Preimplantation genetic diagnosis (PGD) has been applied clinically at over 20 centers around the world. More than a hundred unaffected children have already been born following PGD in over 700 clinical cycles performed for single-gene and chromosomal disorders. This progress was reviewed by the 6th Annual Meeting of the International Working Group on Preimplantation Genetics, organized in association with the 9th International Congress of Human Genetics, Rio de Janeiro, August 18, 1996. Major emphasis was on preimplantation diagnosis of chromosomal aneuptoidies using FISH analysis.
PREIMPLANTATION DIAGNOSIS OF CHROMOSOMAL DISORDERS
At present more than half of PGD cycles have been performed for age-related aneuploidies. FISH analysis with chromosome-specific probes was used in all cases, as metaphase analysis is still too unreliable to be accepted for clinical application. Using FISH analysis of chromosomes X, Y, 13, 18, and 21,523 PGD cycles have been performed in 413 couples, mostly over age 35 years. This has resulted in 115 clinical pregnancies, from which 56 normal babies have already been born (Chicago, Cornell, Atlanta, St. Barnabas). PGD has also been applied for translocations in eight patients (St. Barnabas, Barcelona, Bologna, Hammersmith, University College London), resulting in three births of unaffected children (triplet) and in one ongoing twin pregnancy (St. Barnabas). The following chromosomes were involved in translocations: t(13;14), four cases; t(13;21); t(6;21); t(12;13); and t(12;20).
Despite the obvious progress in PGD of chromosomal disorders, there are still problems to be resolved. There are difficulties in interpretation of high rates of abnormalities in polar body analysis (1-3) and high rates of mosaicism at the cleavage stage (4-6). The possibility of overestimating abnormalities in polar bodies was suggested by the greater number of missing signals compared to the number of extra signals found in the first polar bodies: 6% of abnormal first polar bodies showed missing chromosomes, and 52% showed missing chromatids, compared to 2% showing extra chromosomes and 19% showing extra chromatids (Chicago). Other artifactual results are due to fragmentation of the first polar body in some cases. It is thus important to develop criteria for recording signals in polar bodies, so these clearly differ from those in somatic cells and sperm. The accuracy of genetic analysis of the oocytes may be improved also by testing of both first and second polar bodies. In the presented material only half of the oocytes selected for transfer were tested by both polar bodies; 31% of the oocytes were tested only by the first, and 19% only by the second polar body (Chicago). Even incomplete information on the genotype of the oocytes may increase the chances of avoiding the transfer of abnormal oocytes, particularly when the first polar body is analyzed; however, undetected aneuploidies origi-
